Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

2185 - Measurement of molecular biomarkers to predict tumor response in estrogen receptor positive breast cancer after dose-dense (biweekly) paclitaxel/carboplatin neoadjuvant chemotherapy


10 Oct 2016


Poster display


Kun Wang


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


K. Wang1, T. Zhu2, C. Yang2, Y. Zhang2, L. Zhang2

Author affiliations

  • 1 The Second Department Of Breast Cancer, Guangdong General Hospital, 510000 - Guangzhou/CN
  • 2 The Second Department Of Breast Cancer, Guangdong General Hospital, 510120 - Guangzhou/CN


Abstract 2185


Dose-dense (biweekly) paclitaxel/carboplatin(PC) as neoadjuvant Chemotherapy (NCT) for operable breast cancer is feasible and efficient. This study was to analysis the relationship between the molecular biomarkers and tumor response in estrogen receptor(ER) positive breast cancer.


84 ER-positive breast cancer patients treated with Dose-dense (biweekly) paclitaxel/carboplatin NCT were analyzed for expression of progesrone receptor (PgR), Tau, ki67, HER2, Bcl-2 by immunohistochemistry (IHC), these data were used to test whether these biomarkers can predict tumor response. The primary endpoint was a pathologically complete response (pCR). The second endpoint was the change in tumor size between pre and post NCT.


Univariate analysis showed that HER2 positive (53.85% vs 8.62%, p 


This study investigates the value of traditional biological markers, Bcl-2 and Tau in ER-positive patients treated with dose-dense (biweekly) paclitaxel/carboplatin NCT.

Clinical trial identification


Legal entity responsible for the study



Guangdong General Hospital


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings